Public Group
Active 10 months ago
Monoclonal antibody-based immunotherapies against cancer and other infectious diseases are highly advantageous comparing to conventional therapeutic approaches due to their high specificity and affinity towards well-defined targets. Antibody-drug conjugates (ADCs) inherit such superiorities and more remarkably, expand the therapeutic window of the conjugated drugs (payloads), which are usually highly toxic and diverse in their biochemical nature.
Group Admins
-
creativebiolabs2018 created the group
One-stop ADC Development Service 10 months ago
